Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

  1. Teerlink, J.R.
  2. Diaz, R.
  3. Felker, G.M.
  4. McMurray, J.J.V.
  5. Metra, M.
  6. Solomon, S.D.
  7. Adams, K.F.
  8. Anand, I.
  9. Arias-Mendoza, A.
  10. Biering-Sørensen, T.
  11. Böhm, M.
  12. Bonderman, D.
  13. Cleland, J.G.F.
  14. Corbalan, R.
  15. Crespo-Leiro, M.G.
  16. Dahlström, U.
  17. Echeverria Correa, L.E.
  18. Fang, J.C.
  19. Filippatos, G.
  20. Fonseca, C.
  21. Goncalvesova, E.
  22. Goudev, A.R.
  23. Howlett, J.G.
  24. Lanfear, D.E.
  25. Lund, M.
  26. Macdonald, P.
  27. Mareev, V.
  28. Momomura, S.-I.
  29. O'Meara, E.
  30. Parkhomenko, A.
  31. Ponikowski, P.
  32. Ramires, F.J.A.
  33. Serpytis, P.
  34. Sliwa, K.
  35. Spinar, J.
  36. Suter, T.M.
  37. Tomcsanyi, J.
  38. Vandekerckhove, H.
  39. Vinereanu, D.
  40. Voors, A.A.
  41. Yilmaz, M.B.
  42. Zannad, F.
  43. Sharpsten, L.
  44. Legg, J.C.
  45. Abbasi, S.A.
  46. Varin, C.
  47. Malik, F.I.
  48. Kurtz, C.E.
  49. Show all authors +
Journal:
European Journal of Heart Failure

ISSN: 1879-0844 1388-9842

Year of publication: 2020

Volume: 22

Issue: 11

Pages: 2160-2171

Type: Article

DOI: 10.1002/EJHF.2015 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals